Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 15/20 | 0.56 |
| ▸ | GPR34 | Q9UPC5 | 9/20 | 0.56 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293534 | 1.00 | P2RY10 (0.56) | P2RY10GPR34GPR174 | |
| SCHEMBL16294197 | 1.00 | P2RY10 (0.56) | P2RY10GPR34GPR174 | |
| SCHEMBL9952582 | 1.00 | P2RY10 (0.56) | P2RY10GPR34GPR174 | |
| SCHEMBL3051352 | 0.94 | P2RY10 (0.61) | P2RY10GPR34GPR174 | |
| SCHEMBL479757 | 0.91 | P2RY10 (0.58) | P2RY10GPR34GPR174 | |
| SCHEMBL29728687 | 0.86 | KDM4E (0.47) | P2RY10GPR34GPR174 | |
| SCHEMBL30063078 | 0.86 | KDM4E (0.47) | P2RY10GPR34GPR174 | |
| SCHEMBL28207261 | 0.86 | KDM4E (0.47) | P2RY10GPR34GPR174 | |
| SCHEMBL7455157 | 0.84 | P2RY10 (0.49) | P2RY10GPR34GPR174 | |
| SCHEMBL226745 | 0.83 | PLA2G2C (0.43) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3302436-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | The General Hospital Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | claimed |
| US-20230346989-A1 | FLUOROCARBON NANOEMULSIONS AND USES THEREOF IN IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-02 | — | — | US | disclosed |
| EP-4213892-A1 | FLUOROCARBON NANOEMULSIONS AND USES THEREOF IN IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022061363-A1 | FLUOROCARBON NANOEMULSIONS AND USES THEREOF IN IMAGING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| EP-2611438-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | Pulmatrix, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012109151-A1 | PERMEATION ENHANCERS WITH LIPOSOMES FOR TOPICAL FORMULATIONS | PROFESSIONAL COMPOUNDING CENTERS OF AMERICA, LTD. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012030664-A1 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES | PULMATRIX, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346989-A1 | FLUOROCARBON NANOEMULSIONS AND USES THEREOF IN IMAGING | NAF1, LIPA, SGMS1 | P2RY10 4176/4885GPR34 1834/4885GPR174 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.